Octagos Earns TIME's World's Top HealthTech Companies Recognition for Second Consecutive Year

Octagos is the only cardiac remote monitoring company named in the inaugural 2025 ranking and the 2026 edition, which recognized 500 companies worldwide.

HOUSTON, Sept. 17, 2026 /PRNewswire/ -- Octagos, a leader in cardiac remote monitoring, announced today it has been named one of the World's Top HealthTech Companies of 2026 by TIME and Statista. It is the second consecutive year the company has been recognized, and Octagos is the only cardiac implantable electronic device (CIED) monitoring company named in either edition.

TIME and Statista evaluated thousands of health technology companies based on financial performance (50%), reputation (30%), and online engagement (20%). The 2026 lists recognizes 500 companies worldwide across six categories. Octagos was one of 82 companies recognized in the AI and Data Analytics category, earning a "Very High" performance rating.

Clinical Evidence Behind the Recognition

Octagos pairs Atlas AI™, its proprietary intelligence engine, with review by an IBHRE-certified device specialist before any report reaches a clinic. In a peer-reviewed study published in JACC: Advances, researchers evaluated 690,673 transmissions from 74,217 devices at 78 clinics.¹ Atlas AI alone demonstrated 99.1% sensitivity compared with 70.8% for device specialists reviewing without AI support. Octagos' Two-Brain Approach™, which combines Atlas AI with IBHRE-certified specialist review, demonstrated 99.5% accuracy, 99.1% sensitivity and 99.8% specificity. Together, AI and clinical expertise provide a human-in-the-loop model designed to improve accuracy while keeping clinical judgment at the center of care. 

"We are building toward a future in which healthcare technology is not simply a tool clinicians use, but an intelligent layer woven into how care is delivered," said Dr. Shanti Bansal, founder and CEO of Octagos. "That intelligence should anticipate what teams need, surface what matters sooner and extend their capabilities, giving clinicians more time and capacity to focus on their patients."

Octagos at Scale

Octagos monitors nearly 1,000,000 patients across more than 400 clinical locations in the United States, supporting all major CIED manufacturers, heart failure devices, and ambulatory cardiac monitors in a single workflow.² The company builds bi-directional EHR integrations in-house, at no cost to the clinic, and has processed more than 1 billion pages of transmissions. This real-world operating scale provides the foundation for continued clinical validation and innovation.²

Clinics using Octagos report a 65% reduction in clinical burden and more than 200 staff hours returned each month per 1,000 patients.³ Urgent findings reach the clinic within one hour and routine transmissions within 24 hours, with clinical specialist review included. Octagos prices its service per billable event, so monitoring costs align with clinical reimbursement.

About Octagos

Octagos is modernizing remote cardiac monitoring with AI-powered automation, seamless EHR integrations, and accuracy proven in high-volume, real-world clinics. Atlas AI™ triages cardiac device transmissions to filter nonactionable alerts and surfaces the events that need true clinical attention. Through our Two-Brain Approach™ – combining Atlas AI with IBHRE-certified device specialists – Octagos delivers 99%+ accuracy, sensitivity, and specificity for near-perfect clinical performance. With fast, flexible, and zero-cost bi-directional EHR integrations, Octagos' all-in-one solution helps clinics scale care efficiently without compromise. Recognized by TIME and Statista as one of the World's Top HealthTech Companies in both 2025 and 2026, Octagos is redefining how cardiac care is delivered.

Learn more at www.octagos.com.

REFERENCES

1. JACC: Advances. Retrospective evaluation of 690,673 transmissions from 74,217 devices across 78 U.S. clinics over eight months. Full citation available on request.
2. Data on file. Octagos, 2026.
3. Data on file. Octagos, 2026. Average across clinics using the Two-Brain Approach™; individual results vary.

MEDIA CONTACT
Octagos • [email protected] • octagos.com 

SOURCE Octagos